2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
ASCO® 2024 Insights: "LAURA Study - Osimertinib After Definitive CRT in Patients With Unresectable Stage 3 EGFRm NSCLC"
By
ecancer
FEATURING
Suresh Ramalingam
By
ecancer
FEATURING
Suresh Ramalingam
Login to view comments.
Click here to Login